Key result
Intraperitoneal flecainide successfully converted supraventricular tachycardia in a hydropic fetus that was initially refractory to transplacental treatment.
Why the study?
Supraventricular tachycardia is the most common fetal tachyarrhythmia and if persistent is often associated with fetal hydrops, which can cause intrauterine and neonatal death.
Does intraperitoneal flecainide convert refractory supraventricular tachycardia in a hydropic fetus?
Case Report (n=1)
Does intraperitoneal flecainide convert refractory supraventricular tachycardia in a hydropic fetus?
Intraperitoneal flecainide may be an effective rescue therapy for fetal supraventricular tachycardia with hydrops refractory to transplacental treatment.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for intraperitoneal flecainide in refractory fetal SVT with hydrops; larger prospective studies needed before adoption.
INTRODUCTION: Supraventricular tachycardia is the most common fetal tachyarrhythmia and if persistent often associated with fetal hydrops which can cause intrauterine and neonatal death. CASE PRESENTATION: We present a case of early second trimester supraventricular tachycardia in a hydropic fetus, initially refractory to transplacental treatment. CONCLUSION: The supraventricular tachycardia was successfully treated when supplemented with intraperitoneal flecainide in the fetus.
No takes yet. Share an insight, caveat, or question.
Vedel et al. (2020) conducted a case report in Fetal supraventricular tachycardia with hydrops (n=1). Intraperitoneal flecainide was evaluated on Conversion of supraventricular tachycardia. Intraperitoneal flecainide successfully converted supraventricular tachycardia in a hydropic fetus that was initially refractory to transplacental treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: